Xuelin Wang

Title: Xuelin Wang: Innovator in Monoclonal Antibody Development

Introduction

Xuelin Wang is a notable inventor based in Changchun, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies for medical applications. His work focuses on addressing critical health issues, such as the diagnosis and treatment of infectious diseases.

Latest Patents

Xuelin Wang holds a patent for a hybridoma cell strain and the monoclonal antibody produced therefrom against serine protease of intestinal stage. This invention aims to provide a specific diagnostic method for trichinellosis. The patent describes a hybridoma cell strain deposited under the accession number CGMCC No. 18317. The monoclonal antibody, Ts-ZH68-2A4-Ab, secreted by this hybridoma cell strain, has shown the ability to compete with positive serum from infected pigs for binding to the Ts-ZH68 antigen. The recognition peptide associated with this antibody is GVDRSATCQGDSGGP. This innovation lays the groundwork for developing reagents or vaccines for diagnosing or preventing infections.

Career Highlights

Xuelin Wang is affiliated with Jilin University, where he conducts research and development in the field of biotechnology. His work has been instrumental in advancing the understanding of serological diagnosis methods. He has successfully contributed to the scientific community through his innovative research and patent filings.

Collaborations

Xuelin Wang has collaborated with notable colleagues, including Mingyuan Liu and Xiaolei Liu. Their joint efforts have further enhanced the research output and innovation in their respective fields.

Conclusion

Xuelin Wang's contributions to the field of monoclonal antibody development represent a significant advancement in medical diagnostics. His innovative work continues to pave the way for new methods in the prevention and treatment of infectious diseases.